LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
LLY
776.45
-2.39%↓
JNJ
152.33
+0.12%↑
ABBV
182.26
-2.5%↓
NVO
68.53
+1.17%↑
UNH
308.74
+2.11%↑
24h
Current
Min
Max
Income | 33M -3.1M |
---|---|
Sales | 8.4M 20M |
EPS | -0.06 |
Profit margin | -15.19 |
Employees | 59 |
EBITDA | 11M -5.4M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +146.52% upside |
Next Earnings | 12 sie 2025 |
---|
Market Cap | 67M 492M |
---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
5 sie 2024, 11:25 UTC
Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 23 USD 146.52%
High 25 USD
Low 19 USD
Based on 6 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
6
Buy
0
Hold
0
Sell
Based on 6 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$